Search

Your search keyword '"Asieh Salesi"' showing total 2 results
Start Over Author "Asieh Salesi"
2 results on '"Asieh Salesi"'

1. Atorvastatin and prevention of contrast induced nephropathy following coronary angiography

Author

Peyman Bidram, Farshad Roghani, Hamid Sanei, Zahraparin Hedayati, Allahyar Golabchi, Mehdi Mousavi, Alireza Hajiannejad, Behrouz Pourheidar, Mehdi Mohseni Badalabadi, Maryam Gharaati, Mohammadreza Akhbari, and Asieh Salesi

Subjects
Angiography, atorvastatin, contrast induced nephropathy, prevention, Medicine
Abstract

Background: Contrast induced nephropathy (CIN) is one of the most common complications after radiographic procedures using intravascular radiocontrast media. The aim of the current study was to assess the effect of atorvastatin on prevention of CIN in patients undergoing coronary angiography. Materials and Methods: In a clinical trial study, 200 patients referred for angiography were randomly divided into two groups of using 80 mg atorvastatin and placebo before the procedure. Furthermore, 100 patients who were under chronic treatment of statins were included as the third group. Serum creatinine (Scr) levels before and after the procedure were evaluated and incidence of CIN (post-procedural Scr of >0.5 mg/dl or >25% from baseline) was assessed. Results: Mean age of the participants was 60.06 ± 0.69 years and 276 (92%) were male. There were no significant differences between group with respect to age and gender. In pre-operation atorvastatin, placebo and long term statin groups, the incidence of CIN was 1%, 2% and 1%, and mean changes of Glomerular filtration rate (GFR) was 3.68 ± 1.32, −0.77 ± 1.21 and 1.37 ± 0.86; and mean changes of creatinine (Cr) was −0.05 ± 0.02, 0.02 ± 0.02 and −0.01 ± 0.01 respectively. (P = 0.776, 0.026 and 0.041 respectively). In pre-operation atorvastatin group, Cr decreased, and GFR increased significantly (P = 0.019 and 0.007 respectively). Conclusion: pre-operation short term high dose atorvastatin use was associated with a significant decrease in serum Cr level and increase in GFR after angiography.

Published
2015

2. Risk Factors for Migraine Attacks in Patients Undergoing Treatment for Hepatitis C

Author

Asieh Salesi, Seyed Moayed Alavian, Razie Salesi, and Faraidoon Haghdoost

Subjects
Hemolytic anemia, medicine.medical_specialty, Anemia, Hepatitis C virus, Population, medicine.disease_cause, 01 natural sciences, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Medicine, 0101 mathematics, Risk factor, education, education.field_of_study, business.industry, Ribavirin, General Medicine, Hepatitis C, medicine.disease, Surgery, 010101 applied mathematics, Migraine, chemistry, 030211 gastroenterology & hepatology, business
Abstract

Dear Editor, Migraine, defined as a recurrent unilateral pulsatile headache, which is usually accompanied by nausea, vomiting, phonophobia, and photophobia, is a major cause of chronic headaches. It has been ranked the eight most disabling disorder, and its prevalence is higher in females (17% vs. 6%) (1). Hepatitis C virus (HCV) infection infects more than 170-million individuals worldwide and is as an important healthcare problem. According to published studies, the prevalence of HCV is less than 1% in the general population. A combination of ribavirin, an antiviral nucleoside analogue, and interferon is the most common treatment for chronic hepatitis C (2-5). This method of treatment is also used in occult hepatitis C infections, which is a chronic form (6). HCV treatment was reported to be associated with severe migraine attacks, with the source of the attacks attributed to ribavirin-related hemolytic anemia. Hemolytic anemia is a common and reversible side effect of ribavirin therapy, caused by the hemoglobin (Hb) level decreasing by at least 30 g/L in more than 50% of patients treated with this drug. About 7–10% of ribavirin-treated patients develop severe anemia, with a Hb level of 2 mg/dL or more in the Hb level 2 weeks after the start of treatment require special care (8). The ribavirin dose has to be reduced significantly more often in females than in males. Normally, females have lower baseline Hb levels. This may explain why females have a higher risk of hemolytic anemia then males. Older patients (≥ 55 years) are much more likely than younger patients (≤ 55 years) to require a dose reduction of ribavirin. The underlying reason for the increased prevalence of dose reductions among elderly people is unknown, but it may be associated with the presence of erythrocyte membrane anomalies and renal dysfunction among the elderly. A low baseline platelet count was reported to be another risk factor for the development of more severe ribavirin-induced anemia (2). A significant relationship was reported between the ribavirin dose per kilogram and the incidence of anemia. Anemia was observed to be more common in patients receiving > 12 mg/kg than in those receiving 2 g/dL within 2 weeks after starting the treatment, female sex, older age (≥ 55 years), receiving ribavirin of > 12 mg/kg, and a low baseline platelet count. Patients with these risk factors must receive more care for better management and prevention of developing migraine attacks during the treatment.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results